Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
27/9 05:31
(RTTNews) - Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-11...